Research map: Add-on safinamide and amantadine in Filipino Parkinson’s disease patients with motor fluctuations: a retrospective exploratory cohort study

Back to the article

Papers in this map

  1. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021 · Dongning Su · 2025 · 593 citations · Cited by this paper
  2. Disease modification in advanced Parkinson’s disease: a review and roadmap for paving the way for next-generation interventions · 2026 · Related
  3. Randomized trial of safinamide add‐on to levodopa in Parkinson's disease with motor fluctuations · Rupam Borgohain · 2013 · 292 citations · Cited by this paper
  4. Exploring the relationship between interoception and mental body representation in Parkinson’s disease · 2026 · Related
  5. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times · Ying Jiao Zhao · 2010 · 218 citations · Cited by this paper
  6. Toward the prevention of clinically manifest Parkinson’s disease · 2026 · Related
  7. Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study) · Rajesh Pahwa · 2015 · 153 citations · Cited by this paper
  8. Clinicoepidemiological characteristics of autoimmune encephalitis in the philippines: a multicenter case series study · 2026 · Related
  9. Recent Advances in Drug Therapy for Parkinson's Disease · Hidetomo Murakami · 2022 · 103 citations · Cited by this paper
  10. Visual function and autism spectrum disorder · 2026 · Related
  11. Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence · Sagari Betté · 2018 · 68 citations · Cited by this paper
  12. Pallidotomy for severe Parkinson’s disease dyskinesia and other motor features in a resource-limited setting: the Philippine experience and review of the literature · 2026 · Related
  13. An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease · Min Kyung Kong · 2017 · 46 citations · Cited by this paper
  14. Treatment stability comparison among different ADD-ON therapies in fluctuating Parkinson’s disease patients: the role of clinical and demographic factors · 2026 · Related
  15. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial1 · Giovanni Abbruzzese · 2020 · 46 citations · Cited by this paper
  16. Psychiatric disorders in amyotrophic lateral sclerosis: a short note · 2026 · Related
  17. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuations · Qianqian Wei · 2022 · 29 citations · Cited by this paper
  18. Prevalence and state-dependent patterns of non-motor fluctuations in Parkinson’s disease · 2026 · Related
  19. Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study · Yoshio Tsuboi · 2020 · 25 citations · Cited by this paper
  20. Beyond “Advanced”: proposing Fluctuation-Dominant Parkinson’s disease as a functional alternative to enable timely device-aided therapy · 2026 · Related
  21. Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease · Robert A. Hauser · 2021 · 25 citations · Cited by this paper
  22. Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson’s Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study · Roongroj Bhidayasiri · 2023 · 10 citations · Cited by this paper
  23. Real-world use of Safinamide in motor fluctuating Parkinson’s disease patients in Italy · Roberta Bovenzi · 2023 · 10 citations · Cited by this paper
  24. Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study · Noriko Nishikawa · 2024 · 9 citations · Cited by this paper
  25. Prevalence and Risk Factors for Dyskinesia among Filipino Patients with Parkinson’s Disease · Leah L. Shiong Shu · 2015 · 5 citations · Cited by this paper
  26. Efficacy and safety of safinamide in Parkinson’s disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study · Eungseok Oh · 2024 · 5 citations · Cited by this paper
  27. A Community-based study on the prevalence and predisposing factors of Parkinson’s disease in Barangay Mangilag Sur, Quezon Province, Philippines · Raymond L. Rosales · 2022 · 4 citations · Cited by this paper
  28. Optimized use of safinamide as an add-on therapy in Asian patients with Parkinson’s disease: a narrative review and expert opinion · Jong Sam Baik · 2025 · 2 citations · Cited by this paper
  29. A meta-analysis of the long-term efficacy of Amantadine for Levodopa-induced dyskinesia in Parkinson’s disease · Kayla Williams · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)